Edition:
United Kingdom

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.47EUR
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
€3.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
181,675
52-wk High
€3.71
52-wk Low
€2.37

Chart for

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.88
Market Cap(Mil.): €226.54
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Valneva ‍Total Revenues Up At 109.8 Million Euros

* ‍TOTAL REVENUES OF EUR 109.8 MILLION IN 2017 (2016 - EUR 97.9 MILLION)​

15 Feb 2018

BRIEF-Valneva Expands Its Commercial Operations And Establishes US Infrastructure

* REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

30 Nov 2017

BRIEF-Valneva 9M EBITDA increases to 12.3 million euros

* TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO‍​

09 Nov 2017

BRIEF-Valneva signs contract with US government

* ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT

08 Nov 2017

BRIEF-Valneva H1 EBITDA rises to 7.6 million euros

* ‍EBITDA INCREASED STRONGLY IN H1 2017 REACHING EUR 7.6 MILLION (VERSUS. EUR 4.7 MILLION IN H1 2016)​

31 Aug 2017

Earnings vs. Estimates